title: Metabotropic glutamate receptors for new treatments in schizophrenia.
abstract: Metabotropic glutamate receptors (mGluRs) represent exciting targets for the development of novel therapeutic agents for schizophrenia. Recent studies indicate that selective activation of specific mGluR subtypes may provide potential benefits for not only the positive symptoms, but also the negative symptoms and cognitive impairments observed in individuals with schizophrenia. Although optimization of traditional orthosteric agonists may still offer a feasible approach for the activation of mGluRs, important progress has been made in the discovery of novel subtype-selective allosteric ligands, including positive allosteric modulators (PAMs) of mGluR2 and mGluR5. These allosteric mGluR ligands have improved properties for clinical development and have served as key preclinical tools for a more in-depth understanding of the potential roles of these different mGluR subtypes for the treatment of schizophrenia.
authors.affiliation: Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Herman
authors.forename: M
authors.initials: M
authors.lastname: Bubser
authors.forename: P J
authors.initials: PJ
authors.lastname: Conn
authors.forename: C K
authors.initials: CK
authors.lastname: Jones
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D003071:Cognition / Q000187:drug effects; D006801:Humans; D008024:Ligands; D018094:Receptors, Metabotropic Glutamate / Q000032:analysis / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D012559:Schizophrenia / Q000188:drug therapy*; D015398:Signal Transduction
chemical_list: D008024:Ligands; D018094:Receptors, Metabotropic Glutamate